Kidney Cancer Clinical Trials Consortium
Abstract
Vanderbilt University Medical Center (VUMC) has been an active and engaged participant in the Kidney Cancer Clinical Trials Consortium over the course of the reporting period. VUMChas led the first protocol conducted through the Consortium (Haake, PI) looking at circulating tumor DNA(ctDNA) in advanced renal cell carcinoma (RCC) patients receiving immune-based systemic therapy. Thistrial has accrued 153 patients out of 160 planned and will generate preliminary data for future studies and extramural finding. Further, the first therapeutic study from the Consortium was proposed and is led by anVUMC investigator (Beckermann, PI) investigating the combination of ipilimumab/nivolumab plus a small molecule inhibitor of the adenosine signaling pathway. This trial is accruing patients at MD Anderson and other sites including VUMC are opening imminently. Drs. Beckermann and Rini are active participants at the monthly Consortium meetings providing critical feedback regarding new proposals and the general direction and governance of the Consortium.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2023
- Accession Number
- AD1221793
Entities
People
- Brian I. Rini
Organizations
- Vanderbilt University Medical Center